SciELO - Scientific Electronic Library Online

 
vol.158 issue2Serum anti-neural immunoreactivity in patients with fibromyalgia. Preliminary study author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Gaceta médica de México

On-line version ISSN 2696-1288Print version ISSN 0016-3813

Abstract

MARQUEZ, Lara K. et al. Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic. Gac. Méd. Méx [online]. 2022, vol.158, n.2, pp.115-118.  Epub May 16, 2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.21000804.

In 2019, Mexico was one of the first countries in Latin America to commit resources to achieve hepatitis C elimination by 2030. One year after this commitment, the global COVID-19 pandemic diverted attention to address immediate health needs to combat the spread of the disease. As a result, efforts to implement hepatitis C prevention and management programs were indefinitely postponed. Furthermore, populations at high risk of contracting the hepatitis C virus (HCV) and who bear the greatest burden of HCV national epidemic, including people who inject drugs and people who live with human immunodeficiency virus infection, remain exposed to extreme health disparities, which have potentially been exacerbated during the COVID-19 pandemic. In this article, we discuss the potential impact the COVID-19 pandemic has had on HCV elimination efforts in Mexico and the urgent need to resume them, since without these efforts, HCV elimination goals are likely not be achieved in the country by 2030.

Keywords : Hepatitis C; Mexico; COVID-19; Drugs.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )